7 Undervalued Pharmaceuticals Stocks for Thursday, November 21
Discover the top 7 undervalued Pharmaceuticals stocks for Thursday, November 21 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer’s disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Commentary & Analysis
5 Undervalued Pharmaceuticals Stocks for Friday, October 04
Discover the top 5 undervalued Pharmaceuticals stocks for Friday, October 04 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, May 21
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, May 21 based on AAII’s Stock Grades.Grace Malone
3 Undervalued Biotechnology & Medical Research Stocks for Tuesday, April 09
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Tuesday, April 09 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Biotechnology & Medical Research Stocks for Friday, February 16
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Friday, February 16 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | INM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.6 | $486.8 | 8% |
|
| Shares Out (Mil) | 4.7 | 42.8 | 14% |
|
| Institutional Ownership | 99.9% | 81.8% | 96% |
|
| Float (Mil) | 3.7 | 44.5 | 10% |
|
| Beta | 0.98 | 0.72 | 58% |
|
| Avg Daily Volume (000s) | 70 | 275 | 33% |
|
| Price Change (52-week) |
(23.2%) | 55.6% | 34% |
|
| Growth | INM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (4.3%) | (2.0%) | 35% |
|
| EPS (5yr) | 66.7% | 15.0% | 97 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.1%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | INM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $392 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($11) | 27% |
|
| EPS (TTM) | ($3.121) | ($0.700) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($7) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7 | $494 | 7% |
|
| Valuation | INM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.95 | 2.17 | 88% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | INM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.3% | na |
|
| ROA | (135.0%) | (22.0%) | 4% |
|
| ROE | (173.1%) | (20.6%) | 5% |
|
| Liabilities to Assets | 64.5% | 32.2% | 59% |
|
| F-Score | 2 | 3 | 7% |
|
InMed Pharmaceuticals Inc. did not pass any screens on 10/27/2026.
